Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of malignant plasma cells in bone marrow, bone lesions, renal failure and immunodeficiency. MM is responsible for ∼1% of all cancers and ∼2% of cancer deaths. Both biologically based and immune based therapies offer significant opportunities for improved patient outcome. However, despite recent advances in treatment, multiple myeloma remains an incurable disease. Accordingly it is recognized that improved knowledge of novel, as-yet unidentified, molecules or pathways that improve our understanding of the development of malignant clones of plasma cells will foster development of new therapies.
Citation: Kotwica K, Cioch MB, Dmoszynska A (2011) Expression of Surface Molecules on Multiple Myeloma Cells and their Potential Role in Pathogenesis, Prognosis, and Treatment. J Mol Biomark Diagn 2:103.